- TRADE NAME: Givlaari (Alnylam Pharma Inc)
- INDICATIONS: Adults with acute hepatic porphyria.
- CLASS: Aminolevulinate synthase 1-directed small interfering RNA, Small interfering RNA (siRNA)
- HALF-LIFE: 6 hours
- FDA APPROVAL DATE: 11/20/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP1A2 and CYP2D6 substrates - PREGNANCY: There are no available data with the use of givosiran in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Please login to view the rest of this drug profile.
Page last updated 05/02/2025
